Share on PinterestForeign trainees learn Baduanjin, a traditional breathing and stretching exercise, in Sanya, south China’s Hainan Province, Aug. 7, 2025. Image credit: Xinhua News Agency/Getty ImagesA recent clinical trial...

"Conceptually, you might think, 'Who would do something so stupid?'" -- Elliot Fishman, MD, of Johns Hopkins Medicine in Baltimore, discussing the malicious potential of deepfake X-rays. "Sadly, younger physicians...

NEW ORLEANS -- The more intensive LDL cholesterol target guidelines recommended for secondary prevention in high-risk patients with atherosclerotic cardiovascular (CV) disease improved outcomes in a randomized trial from South...

NEW ORLEANS -- Coronary artery calcium (CAC) scoring was disproportionately less reliable as a screen for atherosclerotic plaque for people of certain races and countries, according to the large international...

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%. Medscape Medical News Source link : https://www.medscape.com/viewarticle/comprehensive-workup-yields-diagnosis-most-nonobstructive-2026a10009je?src=rss...

DENVER -- Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial. The higher of two doses of brepocitinib improved the total dermatomyositis score by...

A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis. Medscape Medical News Source link...

Combination therapies remain key as multiple agents for melasma hit the market. Medscape Medical News Source link : https://www.medscape.com/viewarticle/melasma-new-era-topical-treatment-options-galore-2026a10009j4?src=rss Author : Publish date : 2026-03-29 17:53:00 Copyright for syndicated content...

The JAK1 inhibitor in development for treating nonsegmental vitiligo was superior to placebo on investigator ratings in two phase 3 trials. Medscape Medical News Source link : https://www.medscape.com/viewarticle/upadacitinib-results-significant-improvements-nonsegmental-2026a10009j2?src=rss Author :...

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments. Medscape Medical News Source link...

When the White House announced it was exploring leucovorin as a treatment for autism, the calls from families started pouring in: "Can you prescribe leucovorin for my child?" We experience...

Women who opted for active surveillance (AS) for ductal carcinoma in situ (DCIS) had ipsilateral invasive breast cancer survival (iiBCS) similar to patients who had immediate surgery, a randomized trial...

Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy.The complement inhibitor was granted accelerated approved in 2024; continued approval was contingent on...

As with many skin conditions, TSW can manifest differently with different skin colours. On white skin it glows an intense red, but on black or brown skin it can appear...

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fibrinolysis-treatment-validated-large-trial-acute-2026a10009im?src=rss Author...

NEW ORLEANS -- It may be reasonable for people with atrial fibrillation (Afib) to undergo percutaneous left atrial appendage (LAA) closure even if long-term anticoagulation is an alternative, according to...

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted daily, but keeping up can...

NEW ORLEANS -- Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The...

NEW ORLEANS -- A major advance for the treatment of intermediate-risk pulmonary embolism (PE) arrived with HI-PEITHO's landmark report on ultrasound-facilitated, catheter-directed thrombolysis (CDT). In this hard-to-treat group of acute...

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative. Medscape Medical News Source link...